Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
出版年份 2018 全文链接
标题
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
作者
关键词
Bone marrow fibrosis, Myelofibrosis, Ruxolitinib, Hydroxyurea
出版物
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-03-15
DOI
10.1186/s13045-018-0585-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients
- (2017) Umberto Gianelli et al. HISTOPATHOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
- (2017) Fulvio Massaro et al. Expert Review of Hematology
- The prognostic impact of bone marrow fibrosis in primary myelofibrosis
- (2016) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
- (2016) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
- (2016) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
- (2016) A. A. Zahr et al. HAEMATOLOGICA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
- (2016) A. A. Zahr et al. HAEMATOLOGICA
- Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib
- (2015) Alessandra Iurlo et al. ANNALS OF HEMATOLOGY
- Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study
- (2015) Hans Michael Kvasnicka et al. HISTOPATHOLOGY
- Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
- (2015) Catriona Jamieson et al. Journal of Translational Medicine
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis
- (2014) Danijela Lekovic et al. MEDICAL ONCOLOGY
- High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms
- (2014) Olga Pozdnyakova et al. MODERN PATHOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells
- (2013) Y. Zhang et al. BLOOD
- Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy
- (2013) Claire N. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis
- (2013) Aziz Nazha et al. LEUKEMIA & LYMPHOMA
- Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
- (2013) Thomas Stauffer Larsen et al. LEUKEMIA RESEARCH
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Improving Survival Trends in Primary Myelofibrosis: An International Study
- (2012) Francisco Cervantes et al. JOURNAL OF CLINICAL ONCOLOGY
- The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
- (2012) Umberto Gianelli et al. MODERN PATHOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: A computer-assisted image study
- (2010) Carolin J. Teman et al. LEUKEMIA RESEARCH
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now